Clinical Trials Browser

Terminated × Triple Negative Breast Neoplasms × atezolizumab × Clear all

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Triple Negative Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06067061 2025-06-11

neoBREASTIM

Phase 1/2 Terminated

Triple Negative Breast Neoplasms

NCT04690855 2023-12-04

TARA

Phase 2 Terminated

1 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1/2 Terminated

1 enrolled 6 charts

BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04102618 2022-08-15

AWARE-1

Phase EARLY_PHASE1 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03952325 2021-07-30

CONTESSA TRIO

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03292172 2020-11-06

A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Phase 1 Terminated

Triple Negative Breast Neoplasms

NCT02543645 2018-04-30

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Phase 1 Terminated

BreastDermatologicGenitourinaryHead & NeckThoracic

Clear-cell metastatic renal cell carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Kidney Diseases, Kidney Neoplasms, Melanoma, Neoplasms, Neoplasms by Histologic Type, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Triple Negative Breast Neoplasms